Prevalence of Neutralizing Antibodies against Adenoviruses types -C5, -D26 and -B35 used in vaccination platforms, in Healthy and HIV-Infected Adults and Children from Burkina Faso and Chad

Abstract

AbstractVaccines derived from human adenoviruses (HAdV) are currently being used and trialed against numerous infectious agents. However, pre-existing humoral immunity can impair vaccines efficacy and safety. Strategies to circumvent this immunity often involve the use of vectors with lower seroprevalence. We evaluated HAdV-C5, HAdV-D26 and HAdV-B35 seroprevalence from healthy and HIV-infected populations from Burkina Faso and Chad. Seroprevalence for HAdV-C5 was high and comparable between countries (54%-66%), and the highest in the HIV-infected groups from sub-Saharan regions (∼90%). However, compared to France (4%), seroprevalence for HAdV-D26 was significantly higher in sub- Saharan groups (∼47%). By contrast, HAdV-B35 seroprevalence was low for all groups tested. We also found that HAdV-D26 complexed with immunoglobulins induced strong activation of dendritic cells in vitro. Our study fills gaps in the epidemiological data needed to optimize HAdV-derived vaccines in sub-Saharan regions, and highlights the necessity to better adjust vaccination strategies in Africa.Article summary lineHAdVs Seroprevalence in Burkina Faso and Chad